Literature DB >> 22612116

Potential clinical impact of three-dimensional visualization for fluorescent in situ hybridization image analysis.

Zheng Li, Shibo Li, Zheng Bin, Roy Zhang, Yuhua Li, Huimin Tian, Wei Chen, Hong Liu.   

Abstract

Chromosomal translocation is strong indication of cancers. Fluorescent in situ hybridization (FISH) can effectively detect this translocation and achieve high accuracy in disease diagnosis and prognosis assessment. For this purpose, whole chromosome paint probes are utilized to image the configuration of DNA fragments. Although two-dimensional (2-D) microscopic images are typically used in FISH signal analysis, we present a case where the translocation occurs in the depth direction where two probed FISH signals are overlapped in the projected image plane. Thus, the translocation cannot be identified. However, when imaging the whole specimen with a confocal microscope at 27 focal planes with 0.5-μm step interval, the translocation can be clearly identified due to the free rotation capability by the three-dimensional (3-D) visualization. Such a translocation detection error of using 2-D images might be critical in detecting and diagnosing early or subtle disease cases where detecting a small number of abnormal cells can make diagnostic difference. Hence, the underlying implication of this report suggests that utilizing 3-D visualization may improve the overall accuracy of FISH analysis for some clinical cases. However, the clinical efficiency and cost of using 3-D versus 2-D imaging methods are also to be assessed carefully.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22612116      PMCID: PMC3381014          DOI: 10.1117/1.JBO.17.5.050501

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  12 in total

1.  Acute myeloid leukemia clinical practice guidelines in oncology.

Authors:  Margaret R O'Donnell; Frederick R Appelbaum; Maria R Baer; John C Byrd; Steven E Coutre; Lloyd E Damon; Harry P Erba; Eli Estey; James Foran; Jeffrey Lancet; Lori J Maness; Peter G Maslak; Michael Millenson; Joseph O Moore; Donna Przepiorka; Paul Shami; B Douglas Smith; Richard M Stone; Martin S Tallman
Journal:  J Natl Compr Canc Netw       Date:  2006-01       Impact factor: 11.908

2.  Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases.

Authors:  Joshua F Coleman; Karl S Theil; Raymond R Tubbs; James R Cook
Journal:  Am J Clin Pathol       Date:  2011-06       Impact factor: 2.493

Review 3.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance.

Authors:  D Campana; C H Pui
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

4.  Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900).

Authors:  Gail H Vance; Haesook Kim; Gary A Hicks; Athena M Cherry; Rodney Higgins; Rachael L Hulshizer; Martin S Tallman; Hugo F Fernandez; Gordon W Dewald
Journal:  Leuk Res       Date:  2006-09-22       Impact factor: 3.156

5.  Necessity of bilateral bone marrow biopsies for ancillary cytogenetic studies in the pediatric population.

Authors:  Kate E Grimm; Connie Chen; Lawrence M Weiss
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

6.  Cytogenetic and molecular cytogenetic studies of a variant of t(21;22), ins(22;21)(q12;q21q22), with a deletion of the 3' EWSR1 gene in a patient with Ewing sarcoma.

Authors:  Jiyun Lee; Deborah J Hopcus-Niccum; John J Mulvihill; Shibo Li
Journal:  Cancer Genet Cytogenet       Date:  2005-06

7.  Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol.

Authors:  Ekaterina Kuchinskaya; Mats Heyman; Ann Nordgren; Stefan Söderhäll; Erik Forestier; Peder Wehner; Kim Vettenranta; Olafur Jonsson; Finn Wesenberg; Sigrid Sahlén; Magnus Nordenskjöld; Elisabeth Blennow
Journal:  Br J Haematol       Date:  2011-01-17       Impact factor: 6.998

8.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

Authors:  H Cavé; J van der Werff ten Bosch; S Suciu; C Guidal; C Waterkeyn; J Otten; M Bakkus; K Thielemans; B Grandchamp; E Vilmer
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

9.  Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients.

Authors:  Maria Christina Cox; Paola Panetta; Adriano Venditti; Giovanni Del Poeta; Annibale Franchi; Francesco Buccisano; Anna Tamburini; Luca Maurillo; Sergio Amadori
Journal:  Hematol J       Date:  2003

10.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.